Loading...
•
Mar 31, 2023
EyePoint Pharmaceuticals Q1 2023 Earnings Report
EyePoint Pharmaceuticals reported results for first quarter 2023 and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported a total net revenue of $7.7 million for the first quarter ended March 31, 2023. YUTIQ net product revenue increased by 60% to $7.4 million compared to the first quarter of 2022. The company's cash and investments totaled $122.5 million as of March 31, 2023.
Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023
Enrollment ahead of schedule in the Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic retinopathy (NPDR); trial size reduced based on robust body of clinical evidence and proof-of-concept for vorolanib and EYP-1901
YUTIQ® net product revenue increased 60% to $7.4 million compared with $4.6 million in 1Q 2022
The Company entered into a lease agreement in January for the construction of a 40,000-square-foot standalone commercial manufacturing facility in Northbridge, Massachusetts to support global product supply of EYP-1901 and YUTIQ.
Revenue by Segment
Forward Guidance
The Company expects the cash, cash equivalents and investments on hand at March 31, 2023 and expected net cash inflows from product sales will enable it to fund current and planned operations into the second half of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...